Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Delayed Postoperative Malignant Hyperthermia After Total Intravenous Anesthesia: A Case Report.

Created on 08 Oct 2026

Authors

Jeongeun Lee, Hyungtae Kim, Won Uk Koh, Jaedo Lee, Seeun Jung

Published in

Cureus. Volume 18. Issue 9. Pages e115867. Epub Sep 06, 2026.

Abstract

Malignant hyperthermia (MH) is a rare pharmacogenetic disorder typically triggered by volatile anesthetics or succinylcholine, but its occurrence after total intravenous anesthesia (TIVA) remains exceptional and underreported. Propofol-based TIVA is recommended for MH-susceptible patients to avoid known triggers, yet absolute prevention cannot be guaranteed. A 24-year-old male with prior suspected MH underwent spine surgery under propofol-remifentanil TIVA after strict preventive preparation. Despite stable intraoperative parameters, he developed fever, tachycardia, rigidity, and myoglobinuria 14 hours postoperatively, with markedly elevated creatine kinase and myoglobin levels. Dantrolene administration resulted in rapid clinical improvement. The Malignant Hyperthermia Clinical Grading Scale score of 48 indicated "very likely MH." This case underscores the risk of MH even with TIVA in susceptible patients, emphasizing the need for vigilant monitoring, availability of dantrolene, and preparedness for delayed onset regardless of the anesthetic technique used.

PMID:
42846123
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement